- Home
- NB vs LCTX Comparison
NB vs LCTX Comparison
Compare NB & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NB
- LCTX
- Stock Information
- Founded
- NB 1987
- LCTX 1990
- Country
- NB United States
- LCTX United States
- Employees
- NB N/A
- LCTX N/A
- Industry
- NB Metal Mining
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NB Basic Materials
- LCTX Health Care
- Exchange
- NB Nasdaq
- LCTX Nasdaq
- Market Cap
- NB 132.6M
- LCTX 107.3M
- IPO Year
- NB N/A
- LCTX N/A
- Fundamental
- Price
- NB $2.51
- LCTX $0.68
- Analyst Decision
- NB Strong Buy
- LCTX Strong Buy
- Analyst Count
- NB 2
- LCTX 5
- Target Price
- NB $4.13
- LCTX $4.20
- AVG Volume (30 Days)
- NB 458.7K
- LCTX 1.1M
- Earning Date
- NB 05-08-2025
- LCTX 05-13-2025
- Dividend Yield
- NB N/A
- LCTX N/A
- EPS Growth
- NB N/A
- LCTX N/A
- EPS
- NB N/A
- LCTX N/A
- Revenue
- NB N/A
- LCTX $9,557,000.00
- Revenue This Year
- NB N/A
- LCTX N/A
- Revenue Next Year
- NB N/A
- LCTX $232.66
- P/E Ratio
- NB N/A
- LCTX N/A
- Revenue Growth
- NB N/A
- LCTX 19.42
- 52 Week Low
- NB $1.27
- LCTX $0.37
- 52 Week High
- NB $4.15
- LCTX $1.15
- Technical
- Relative Strength Index (RSI)
- NB 54.54
- LCTX 66.86
- Support Level
- NB $2.25
- LCTX $0.48
- Resistance Level
- NB $2.64
- LCTX $0.70
- Average True Range (ATR)
- NB 0.14
- LCTX 0.05
- MACD
- NB 0.01
- LCTX 0.02
- Stochastic Oscillator
- NB 70.39
- LCTX 73.55
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.